Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: Human immunodeficiency virus type 1-infected patients from two geographical areas in Spain

Journal of Human Virology

Volumn 3, Issue 3, 2000, Pages 150-156

  Pérez Alvarez, Lucia ^a   Villahermosa, Maria Luisa ^a   Cuevas, Maria Teresa ^a   Delgado, Elena ^a   Manjón, Nuria ^a   De Parga, Elena Vázquez ^a   Medrano, Leandro ^a   Contreras, Gerardo ^a   Thomson, Michael M ^a   Colomo, Concepción ^b   Taboada, Jose Antonio ^c   Nájera, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Programa de Prevencion del Sida   (Spain)

^c Xunta de Galicia ^*  (Spain)

Author keywords

Antiretroviral treatment; HIV 1 genotypes; Resistance mutations; Spanish patients

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PREVALENCE; PRIORITY JOURNAL; SPAIN;

COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; POINT MUTATION; PROTEASE INHIBITORS; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SPAIN; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1642633526     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Richman DD. Antiviral drug resistance: issues and challenges. In: Richman DD, ed. Antiviral drug resistance. Chichester, U.K.: John Willey & Sons Ltd., 1996:1-9.
2. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996;276:146-154.
3. BHIVA Guideliness Co-ordinating Committee. British HIV association guideliness of HIV seropositive individuals. 1997;349:1086-1092.
4. Ho D, Neumann A, Perelson A, et al. Rapid turnover of plasma virus and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
5. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span and viral generation time. Science 1996;271:1582-1586.
6. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-489.
7. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994;10:1479-1488.
8. Nájera I, Holguín, Quiñones-Mateu ME, et al. Pol gene quasiespecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:25-31.
9. Lech WJ, Wang G, Yang YL, et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-2043.
10. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-1983.
11. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-311.
12. th Conference on Retroviruses and Opportunistic Infections; January 31 to February 4, 1999; Chicago, IL.
13. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998,339:1803-1809.
14. Villahermosa ML, Contreras G, Pérez-Alvarez L, et al. Evaluation of mixtures of wild type HIV-1 and HIV-1 with resistance mutations against reverse transcriptase inhibitors. Antiviral Ther 1998;3:221-227.
15. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutation in the human immunodeficiency virus type reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
16. Boom R, Sol CJ, Salimans MM. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28: 495-503.
17. Hirsch MS, Conway B, Dáquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA 1998;279:1984-1991.
18. Perrin L, Telenti A. HIV treatment failure: testing for resistance in clinical practice. Science 1998;280:1871-1873.
19. rd International Workshop on HIV Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, CA.
20. rd International Workshop on HIV Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, CA,
21. Fontaine E, Lambert C, Servais J, et al. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients. J Hum Virol 1998;1:451-456.
22. rd International Workshop on HIV Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, CA.
23. nd International Workshop on HIV Drug Resistance and Treatment Strategies; June 24-27, 1998; Lake Maggire, Italy.
24. nd International Workshop on HIV Drug Resistance and Treatment Strategies; June 24-27, 1998; Lake Maggire, Italy.
25. nd International Workshop on HIV Drug Resistance and Treatment Strategies; June 24-27, 1998; Lake Maggire, Italy.
26. th Conference on Retroviruses and Opportunistic Infections; January 31 to February 4, 1999; Chicago, IL.
27. Kozal M, Leahy N, Agar A, et al. Prevalence of HIV-1 drug resistance mutations in antiretroviral-naive patients at an inner city University of Miami HIV clinic in Miami, FL, 1997. Paper presented at: 2nd International Workshop on HIV Drug Resistance and Treatment Strategies; June 24-27, 1998; Lake Maggire, Italy.
28. Verbiest W, Schel P, Conant M, et al. An epidemiological prospective survey assessing the prevalence in 230 HIV-1-positive antiretroviral-naive patients from the USA. Paper presented at: 3rd International Workshop on HIV Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, CA.
29. Cesaire R, Dos Santos G, Abel S, et al. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquir Immune Defic Syndr 1999;22:401-405.
30. Gómez Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998;12:1015-1020.
31. Soriano V. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients. Antiviral Ther 1999;4(suppl 3):57-63.
32. Villahermosa ML, Thomson MM, Vázquez de Parga, et al. Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load. J Hum Virol 2000;3:27-34.
33. Dejong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and out-growth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci U S A 1996;93:5501-5506.
34. Boden D, Hurley A, Zhang LQ, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282: 1135-1141.
35. Salomón H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000;14:F17-F23.
36. Iversen AKN, Shafer RW, Werhrly K, et al. Multidrug resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1997;70:1086-1090.
37. Kavlick MF, Wyvill K, Yarchoan R, et al. Emergence of multi-dideoxynucleoside-resistante human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Inf Dis 1998;98:1506-1513.
38. Schmit JC, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant(MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998;12:2005-2015.
39. Pellegrin T, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999;13:1703-1709.
40. Kemp S, Bloor S. Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance. Paper presented at: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; June, 1997; St. Petersburg, FL.
41. Loveday C, Devereux H, Huckett L, et al. High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population. AIDS 1999;13:627-628.
42. Bloor S, Hertogs K, Desmet IR, et al. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples [abstract]. Antiviral Ther 1998;3(suppl. 1):13.
43. Whitcomb J, Limoli K, Wrin T, et al. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1 [abstract]. Antiviral Ther 1998;3(suppl 1):14.
44. Winters M, Coolley K, Girard Y, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998;102:1769-1775.
45. de Antoni A, Foli A, Lisziewicz J, et al. Mutations in the pol gene of HIV-1 in infected patients, receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903.
46. de Jong JJ, Goudsmit J, Lukashov W, et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999;13:75-80.
47. Sugiura W, Matsuda M, Matsuda Z, et al. Identification of insertion mutations in HIV-reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. J Hum Virol 1999;2:146-153.
48. Rakik A, Ait-Khaled M, Griffin P, et al. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. J Acquired Immune Defic Syndr 1999;22:139-145.
49. Imamichi T, Sinha T, Imamichi H, et al. High-level resistance to 3′-azido-3'′-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000;74:1023-1028.
50. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to human immunodeficiency virus type 1 proteinase inhibitors:mutations, kinetics and frequencies. J Infect Dis 1996;173:1379-1387.